AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$TAK

Duprey Lauren Rusckowski sold $640K of TAK

Duprey Lauren Rusckowski (Chief Transformation Officer) sold 34,535 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $18.54 ($0.64M total) on 2026-09-14.

Original reporting
SEC EDGAR · Duprey Lauren Rusckowski
Published Sep 16, 2026, 1:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Bearish
medium confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKBearishLow
01

Why it matters

The disclosed sale adds a data point for assessing insider sentiment but is unlikely to move the stock significantly.

02

Market read

A modest insider sale from a senior officer; limited trading relevance.

03

What to watch

Potential tax planning or diversification motives for the officer are not disclosed.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider trades; investors monitor them for cues on management sentiment.

Company-level read

Ticker impact

$TAKBearishMedium confidence
Context

Chief Transformation Officer sold 34,535 shares for $640,279, a primary Form 4 insider sale.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is modest ($640k) but involves a C‑suite officer; market may react negatively to insider sell signals.

Market effects

Sector

Minimal impact on the pharmaceutical sector; isolated insider transaction.

Regional

Limited to investors tracking Takeda; no broader regional effect.

Global

Low; does not affect global markets.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Officer
    Duprey Lauren Rusckowski

    Chief Transformation Officer of Takeda Pharmaceutical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min